DYNC1I2 Antikörper (AA 61-160)
Kurzübersicht für DYNC1I2 Antikörper (AA 61-160) (ABIN1713772)
Target
Alle DYNC1I2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 61-160
-
Kreuzreaktivität
- Maus
-
Homologie
- Human,Rat,Dog,Sheep,Pig,Horse,Rabbit
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human DYNC1I2
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200
ICC 1:100-500 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- DYNC1I2 (Dynein, Cytoplasmic 1, Intermediate Chain 2 (DYNC1I2))
-
Andere Bezeichnung
- DYNC1I2
-
Hintergrund
-
Synonyms: Cytoplasmic dynein 1 intermediate chain 2, Cytoplasmic dynein intermediate chain 2, Dynein intermediate chain 2, cytosolic, DH IC-2, DC1I2_HUMAN, DNCI2, DNCIC2, Dynein cytoplasmic intermediate polypeptide 2.
Background: The inner- and outer-arm dyneins, which bridge between the doublet microtubules in axonemes, are the force-generating proteins responsible for the sliding movement in axonemes. The intermediate and light chains, thought to form the base of the dynein arm, help mediate attachment and may also participate in regulating dynein activity. This gene encodes an intermediate chain dynein, belonging to the large family of motor proteins. Mutations in this gene result in abnormal ciliary ultrastructure and function associated with primary ciliary dyskinesia (PCD) and Kartagener syndrome. [provided by RefSeq, Jul 2008].
-
Pathways
- M Phase
Target
-